ClinicalTrials.gg
CompletedNCT02333773IREUpdated Sep 5, 2021

Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli

An interventional study of Irreversible electroporation (IRE) in Liver Cancer, sponsored by Fuda Cancer Hospital, Guangzhou. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2021-09-05.

Sponsored by Fuda Cancer Hospital, Guangzhou · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Liver Neoplasms by Fuda Cancer Hospital, Guangzhou — none open to participants now, none under way, none of them phase 3. Liver Neoplasms · Fuda Cancer Hospital, Guangzhou.

Enrollment
12th of 13
15 · median 36
Started
2015
with 5 others
No phase
3 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Liver Neoplasms by Fuda Cancer Hospital, Guangzhou, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2015, is one of 3 with no phase, and was the 3rd registered.

Liver Neoplasms

1,346 studies on the registry are indexed under Liver Neoplasms; 335 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

None of the 14 studies in Liver Neoplasms by Fuda Cancer Hospital, Guangzhou is open now. The open studies under Liver Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Liver Neoplasms by Fuda Cancer Hospital, Guangzhou as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.

Read the detailed description

By enrolling patients with unresectable Portal venous tumor emboli adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for unresectable Portal venous tumor emboli.

03

Conditions studied

  • Liver Cancer

Browse trials for

Keywords

  • irreversible electroporation
  • Portal venous tumor emboli
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Liver cancer diagnosed by positive or non-invasive criteria,
  • Liver cancer with Portal venous tumor emboli,
  • Not suitable for surgical resection or transplantation,
  • class A,B
  • (ECOG) score of 0-1,
  • A ratio > 50%,
  • count > 80x10\^9/L,
  • Ability of patient to stop anticoagulant and anti-platelet therapy for seven days prior to and seven days post NanoKnife procedure,
  • Able to comprehend and willing to sign the written form (ICF),
  • Have a of at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Cardiac insufficiency, ongoing coronary artery disease or arrhythmia,
  • Any active implanted device (eg Pacemaker),
  • Women who are pregnant or women of who are not using an acceptable method of ,
  • Have received treatment with an agent/ procedure within 30 days prior to treatment with the NanoKnife™ LEDC System,
  • Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Group A

    irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli

    Procedure: Irreversible electroporation (IRE)

  • Experimental
    Group B

    irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli

    Procedure: Irreversible electroporation (IRE)

  • Experimental
    Group C

    irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli

    Procedure: Irreversible electroporation (IRE)

Interventions

  • ProcedureIrreversible electroporation (IRE)

    Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.

    Also known as: NanoKnife

06

What researchers measure

Primary outcomes

  1. Safety (adverse effects)

    adverse effects

    Time frame: 6 month

Secondary outcomes

  1. Efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)

    The primary objective of this project is to evaluate the efficacy (percentage of lesions that show no sign of recurrence 12 months after IRE)

    Time frame: 12 months

  2. Voltage (A minimum and maximum range of voltage for safe and effective IRE)

    A minimum and maximum range of voltage for safe and effective IRE will be analyzed for optimal choice.

    Time frame: 3 months

  3. Progress free disease (PFS)

    Patients will be followed for 12 months after IRE for PFS assessing.

    Time frame: 12 months

  4. Overall survival (OS)

    Patients will be followed for 36 months after IRE for OS analyzed.

    Time frame: 36 months

07

Study locations

1 site
  • Fuda Cancer Hospital
    Guangzhou, Guangdong 510665, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Dec 2020, 71 months.

Of 149 non-industry interventional studies with no phase under Liver Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 82. This study's 71 months is above that.

Counting every sponsor, half of 168 studies reached it within 39 months; a quarter within 18 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 7, 2015
StartActual
Jan 1, 2015
Primary completionActual
Dec 1, 2020
CompletionActual
Jan 1, 2021
Last update
Sep 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02333773
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Jan 1, 2015
Primary completion
Dec 1, 2020
Completion
Jan 1, 2021
Last update
Sep 5, 2021

Study contacts

Lizhi Niu, PHD
study chair · Fuda Cancer Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion